Trial · NCT01697709
Quetiapine Pharmacotherapy for Cannabis Dependence
NCT01697709, Phase 2, Completed, New York State Psychiatric Institute; results first posted 2019-02-05
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Quetiapine Pharmacotherapy for Cannabis Dependence. Trials, record NCT01697709. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01697709
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Quetiapine Pharmacotherapy for Cannabis Dependence
- NCT number
- NCT01697709
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 130 participants, actual
- Lead sponsor
- New York State Psychiatric Institute
- Conditions
- Cannabis Dependence
- Interventions
- Quetiapine, Placebo
- First posted
- 2012-10-02
- Last updated
- 2019-03-05
- Results first posted
- 2019-02-05
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Marijuana Use, Daily Dollar Averaged Over 7 Days During Each of 12 Weeks of Study | 12 weeks or length of participants involvement | The median daily dollar value of marijuana used averaged over a one-week period for each of the 12 weeks as recorded by the Timeline Followback method |
| Primary | Number of Participants Stratified by Marijuana Abstinence Days Per Week | 12 weeks or length of participation | The number of abstinent days per week over the 12 weeks of study as recorded by the Timeline Followback method. High Use group defined as 0-2 abstinent days per week, Medium Use Group as 3-5 abstinent days per week and Low Use Group as 6-7 abstinent days per week. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Marijuana Use, Daily Dollar Averaged Over 7 Days During Each of 12 Weeks of Study | 12 weeks or length of participants involvement | dollars | MEDIAN | |
| PRIMARY | Number of Participants Stratified by Marijuana Abstinence Days Per Week | 12 weeks or length of participation | participants were included in the weekly analysis who were still active in the trial at each given week. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group96
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Marijuana Use, Daily Dollar Averaged Over 7 Days During Each of 12 Weeks of Study | Placebo | week 1 | 14.00 | Inter-Quartile Range 5.42 to 21.25 | dollars |
| Marijuana Use, Daily Dollar Averaged Over 7 Days During Each of 12 Weeks of Study | Quetiapine | week 1 | 7.00 | Inter-Quartile Range 3.18 to 12.86 | dollars |
| Marijuana Use, Daily Dollar Averaged Over 7 Days During Each of 12 Weeks of Study | Placebo | week 2 | 10.00 | Inter-Quartile Range 2.86 to 22.00 | dollars |
| Marijuana Use, Daily Dollar Averaged Over 7 Days During Each of 12 Weeks of Study | Quetiapine | week 2 | 8.00 | Inter-Quartile Range 3.02 to 12.70 | dollars |
| Marijuana Use, Daily Dollar Averaged Over 7 Days During Each of 12 Weeks of Study | Placebo | week 3 | 7.14 | Inter-Quartile Range 2.64 to 17.69 | dollars |
| Marijuana Use, Daily Dollar Averaged Over 7 Days During Each of 12 Weeks of Study | Quetiapine | week 3 | 5.86 | Inter-Quartile Range 3.29 to 11.61 | dollars |
| Marijuana Use, Daily Dollar Averaged Over 7 Days During Each of 12 Weeks of Study | Placebo | week 4 | 6.43 | Inter-Quartile Range 1.61 to 16.25 | dollars |
| Marijuana Use, Daily Dollar Averaged Over 7 Days During Each of 12 Weeks of Study | Quetiapine | week 4 | 5.71 | Inter-Quartile Range 2.57 to 12.00 | dollars |
| Marijuana Use, Daily Dollar Averaged Over 7 Days During Each of 12 Weeks of Study | Placebo | week 5 | 6.43 | Inter-Quartile Range 1.07 to 17.86 | dollars |
| Marijuana Use, Daily Dollar Averaged Over 7 Days During Each of 12 Weeks of Study | Quetiapine | week 5 | 4.29 | Inter-Quartile Range 1.43 to 9.29 | dollars |
1 to 10 of 96Source ClinicalTrials.gov
See all 96 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Placebo | 64 | |
| Overall Study | STARTED | Quetiapine | 66 | |
| Overall Study | COMPLETED | Placebo | 34 | |
| Overall Study | COMPLETED | Quetiapine | 38 | |
| Overall Study | NOT COMPLETED | Placebo | 30 | |
| Overall Study | NOT COMPLETED | Quetiapine | 28 |
Source ClinicalTrials.gov
Adverse events8
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Hypertension | Cardiac disorders | Placebo | 24 | 64 | 24 |
| other | Hypertension | Cardiac disorders | Quetiapine | 36 | 66 | 36 |
| other | Hyperglycemia | General disorders | Placebo | 15 | 64 | 15 |
| other | Hyperglycemia | General disorders | Quetiapine | 18 | 66 | 18 |
| other | Dyslipidemia | Endocrine disorders | Placebo | 11 | 64 | 11 |
| other | Dyslipidemia | Endocrine disorders | Quetiapine | 10 | 66 | 10 |
| other | drowsiness | General disorders | Placebo | 3 | 64 | 3 |
| other | drowsiness | General disorders | Quetiapine | 8 | 66 | 8 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Placebo | 0 | 64 |
| Total, all-cause mortality | Quetiapine | 0 | 66 |
| Total, other adverse events | Placebo | 34 | 64 |
| Total, other adverse events | Quetiapine | 46 | 66 |
| Total, serious adverse events | Placebo | 0 | 64 |
| Total, serious adverse events | Quetiapine | 0 | 66 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01DA031826 | Quetiapine Pharmacotherapy for Cannabis Dependence | MARIANI, JOHN J | NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC | NATIONAL INSTITUTE ON DRUG ABUSE | 2012 to 2015 |
Source NIH RePORTER
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Quetiapine vs Placebo: deaths from any cause | Trial comparisons |
| Quetiapine vs Placebo: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01697709
GET https://conductscience.org/api/trials/v1/NCT01697709/results?page=2